SPC
CGTX icon

Sigma Planning Corp’s Cognition Therapeutics CGTX Stock Holding History

Sigma Planning Corp’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$257K Buy
337,765
+121,600
+56% +$142K 0.01% 1111
2025
Q4 		$295K Buy
216,165
+89,075
+70% +$145K 0.01% 1039
2025
Q3 		$172K Sell
127,090
-20,900
-14% -$28.5K ﹤0.01% 1233
2025
Q2 		$45.8K Sell
147,990
-460,400
-76% -$155K ﹤0.01% 1232
2025
Q1 		$256K Sell
608,390
-6,100
-1% -$3.58K 0.01% 1028
2024
Q4 		$431K Buy
614,490
+417,300
+212% +$206K 0.01% 790
2024
Q3 		$92.4K Buy
197,190
+25,050
+15% +$25.8K ﹤0.01% 1175
2024
Q2 		$286K Buy
172,140
+12,700
+8% +$25.3K 0.01% 946
2024
Q1 		$290K Buy
159,440
+130,890
+458% +$270K 0.01% 974
2023
Q4 		$52.8K Buy
+28,550
New +$37.8K ﹤0.01% 825

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Sigma Planning Corp's CGTX Position: Q1 2026 in Review

Sigma Planning Corp increased its Cognition Therapeutics (CGTX) stake by 56% in Q1 2026, buying an estimated $142K and bringing the position to 337,765 shares worth $257K. The position accounts for 0.01% of the portfolio, ranked #1111.

Sigma Planning Corp first reported a position in CGTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $431K in Q4 2024. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Sigma Planning Corp held 337,765 shares of Cognition Therapeutics worth $257K as of Q1 2026.
  • Sigma Planning Corp bought 121,600 Cognition Therapeutics shares in Q1 2026, an estimated $142K.
  • Cognition Therapeutics made up 0.01% of Sigma Planning Corp's portfolio in Q1 2026, its #1111 holding.
  • Sigma Planning Corp first reported a position in Cognition Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Sigma Planning Corp's Cognition Therapeutics position peaked at $431K in Q4 2024.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.